Agreement to sell Agilex Biolabs to Novotech
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Healius aims to unlock shareholder value through this sale while focusing on its core Pathology business. The sale is anticipated to leave Healius in a net cash position, with further details on the use of proceeds to be provided later.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Healius
- Ceasing to be a substantial holder
- Change in substantial holding
- Trading Halt
- Becoming a substantial holder
- 2026 Appendix 4G
Later from Healius
- Change in substantial holding from MUFG
- Ceasing to be a substantial holder from MUFG
- Becoming a substantial holder from MUFG
- 2026 AGM - Chair & CEO Addresses
- 2026 AGM - CEO Presentation
Follow Healius into a list and get an email when it puts out news.
Follow Healius